Lentiviral vectors pseudotyped with vesicular stomatitis virus glycoprotein (VSV-G) 
Introduction
At present, lentivector-mediated gene transfer has shown considerable promise for in vitro and in vivo gene therapy studies.
1,2 Most current lentiviral vectors are based on human immunodeficiency virus (HIV) type 1 which, in addition to the gag, pol and env coding regions in the genome flanked by the long terminal repeats (LTR), contains several accessory and regulatory proteins, including Tat, Rev, Vif, Vpr, Vpu and Nef. A transient, threecomponent, HIV-based vector system consisting of a packaging construct, a transfer vector, and a vesicular stomatitis virus glycoprotein (VSV-G) envelope has been described and widely used. [3] [4] [5] [6] [7] [8] In this system, the viral particles were pseudotyped with the envelope of VSV-G, which is structurally stable, enabling ultracentrifugal concentration of virions to high titres. 9 Several reports have demonstrated that the HIV-based vectors effectively transduced dividing and nondividing cells in vitro and in vivo with expression of genes of interest in a sustained fashion in cells such as haematopoietic stem cells, 6, 10 Other lentivectors, such as those based on the feline immunodeficiency virus (FIV), 12 equine infectious anaemia virus (EIAV), 13 caprine arthritis/encephalitis virus (CAEV), 14 Jembrana disease virus (JDV) 15 and visna virus, 16 are examples of recently developed non-primate lentiviral vectors. Efficient gene transfer to various cells by some of the vectors has also been demonstrated.
The efficiency of gene transfer and term of gene expression largely depend upon the total number of vector particles delivered per target cell (multiplicity of infection, MOI). Generally, a high MOI is needed for satisfactory levels of VSV-G pseudotyped lentivectormediated gene transfer and expression. Some studies have employed MOIs of 50-300 of HIV-based lentivectors for ex vivo gene transfer to haematopoietic cells 6 or up to 1000 for dendritic cells. 11 Therefore, for the development of efficient gene transfer protocols for in vivo gene delivery to large animals or humans that require efficiency and long-term gene expression, preparation of large volumes of high-titre vector is a prerequisite. However, although there are several protocols that exist to concentrate small 17, 18 and large volumes of murine Moloney leukemia virus (MMoLV)-based vectors, 19 ultracentrifugal concentration at 50 000 g for 2 h is the only reliable method that is currently in use for harvesting VSV-G pseudotyped lentivectors. Because rotors that are usable at this ultra-high speed generally have a small volume capacity (6 × 30-50 ml), the attainment of large volumes of high-titre viral vectors is tedious and timeconsuming to perform. 19 Other shortcomings of ultracentrifugation are that it also concentrates marker gene proteins 20 or dyes, such as phenol red in the medium. 18 Cationic molecules such as poly-l-lysine (PLL) have been used to enhance viral vector and nonviral vectormediated gene transfer. 21, 22 In the delivery of nonviral DNA into cells, the positive electrostatic charge of PLL binds and compacts the negatively charged DNA to form particles that facilitate DNA entry into the cell membrane. 21, 22 Polycationic materials also formed complexes with adenovirus improving the efficacy of target cell entry. 23 We hypothesize that treatment of the lentivector stocks with PLL may enable PLL and lentivector particles (especially the VSV-G envelope) to form complexes. Precipitation of those complexes should be easier than that of free viral vector particles alone, thus allowing concentration by low-speed centrifugation. Also, low-speed concentration should avoid the precipitation of unwanted proteins or dyes in supernatant as occurs by ultracentrifugation. Furthermore, because rotors that are suitable for low-speed centrifugation have a larger capacity (6 × 500 ml) than those for ultracentrifugation (6 × 30-50 ml), harvesting large volumes of high-titre viral vectors from a larger volume of the virus-producing cells (VPCs) supernatant should be possible.
To test these hypotheses, we mixed different amounts of PLL with lentiviral VPCs supernatants under different incubation conditions and centrifugation speeds and compared them directly with ultracentrifugation. We also investigated the mechanisms of low-speed concentration.
Results

Optimal conditions for PLL-assisted concentration of lentiviral vectors
We started by testing the optimal amount of PLL needed for maximum recovery of lentiviral vectors. Aliquots of 10 ml of viral vector supernatant at a known vector titre of 1 × 10 6 TU/ml were used and mixed with increasing amounts of PLL from 0.0025% to 0.01% (w/v). The mixtures were then incubated for 30 min at 4°C, followed by centrifugation at 4000 g. After centrifugation, the aqueous layer was gently discarded and the remaining precipitates were resuspended in 500 l of DMEM, which was then subjected to vector titre determination. Figure 1a shows that mixing PLL with supernatant harvested from VPCs at 0.005% (w/v) enabled concentration of the viral vector to 3.8 × 10 6 TU/ml. Increasing the concentration of PLL to 0.0075% did not increase the recovery and further increase of the amount to 0.01% decreased the recovery. In non-PLL/associated controls, the viral titre remained at about 1 × 10 6 TU/ml. These results demonstrated that pre-treatment of VSV-G pseudotyped lentivector superntant with PLL at 0.005% enabled precipitation of PLL lentivector complexes and concentration of lentivectors.
Using the same amounts of PLL at 0.005%, we further examined the effects of different incubation periods on the efficiency of vector recovery. Incubation of PLL/lentivector mixtures from 5, 15, 30 min or 1 h resulted in similar efficiency of vector concentration at about 3.8 × 10 6 TU/ml. Viral vector titre was slightly higher (3.81 × 10 6 TU/ml) when incubation was for 30 min ( Figure 1b) . These results suggested that PLL and viral vector particles interacted quickly and 30 min incubation of PLL/VPC mixture was sufficient for the pretreatment procedure.
Figure 1 Effects of various conditions of PLL treatment on viral vector recovery. Viral vector titres were determined by transduction of 293T cells with a marker gene, GFP. The values represent mean ± s.e.m. (n = 3). (a) Effects of various amounts of cationic materials on viral vector recovery. Various concentrations of PLL
Having established the amount of PLL and the time of incubation that were needed for precipitation, we then titrated the effects of various speeds (from 4000 g to 12 000 g) as well as duration of centrifugation (from 1 to 4 h) on the efficiency of vector recovery. Experiments were also performed using aliquots of 10 ml of supernatant with a known titre of 1 × 10 6 TU/ml. As shown in Figure 1c and d, the optimal effect was obtained when centrifugation was performed for 2 h at 10 000 g, which resulted in 7.5 × 10 6 TU/ml vector recovery. For reasons that are unknown, extended centrifugation up to 4 h halved the recovery.
Thus, taken together, the optimal conditions for the maximum recovery of PLL-associated lentivectors are: PLL added to viral vector supernatant at 0.005%, incubated at 4°C for 30 min and then centrifuged at 10 000 g for 2 h at 4°C. This procedure will be referred to as 'PLL treatment' throughout the study.
Comparison of PLL treatment with ultracentrifugation for harvesting lentivector
To validate the optimal condition for vector concentration, we next determined how PLL treatment compared with the current standard procedure, ultracentrifugation. Two series of experiments were performed. In the first one, duplicate aliquots of 30 ml of viral vector suspension at a known vector titre of 1 × 10 6 TU/ml were subjected either to ultracentrifugation or PLL treatment. Figure 2a showed that the efficiency of vector recovery using PLL treatment was higher than by ultracentrifugation, ie 8.8 × 10
6 TU/ml versus 5.5 × 10 6 TU/ml (P Ͻ 0.05). In the second experiment, freshly harvested, duplicate aliquots of 30 ml of VPC supernatant with unknown titre were subjected either to ultracentrifugation or PLL treatment or as unconcentrated viral stock. While the vector titre from the unconcentrated VPC supernatant was 1.1 × 10 6 TU/ml, it was 2.7 × 10 7 TU/ml from the PLL treatment and 1.4 × 10 7 TU/ml (P Ͻ 0.02) by ultracentrifugation. Thus, the new method concentrated the viral vector 25-fold, double that of the ultracentrifugation method (12.7-fold) (Figure 2b ).
To validate further the efficiency of vector recovery, viral vector titres were also estimated using a p24 assay (NEN, Life Science, Boston, MA, USA). In this experiment, freshly harvested viral vector supernatants were concentrated either by ultracentrifugation or by PLL treatment followed by an ELISA-based p24 assay. Figure  2c showed that the PLL treatment had a 25% higher p24 value than the ultracentrifugation group, consistent with the result of viral titre determined by the green fluorescent protein (GFP) marker gene, confirming that PLL treatment is a more efficient method for concentration of lentivector than ultracentrifugation.
Harvesting large volumes of high-titre lentivectors using PLL treatment
Having validated the PLL treatment method, we then determined whether the same protocol would work for harvesting large volumes of lentivectors. Packaging of the lentivector was scaled up from 10-cm plates to multiple 40 ml flasks and approximately 3000 ml of VPC supernatant was collected. After setting aside 5 ml of unconcentrated VPC supernatant for vector titre determination, the remainder was subjected to PLL treatment, which was performed in 500 ml polypropylene centrifugation bottles using the GS-3 rotor (6 × 500 ml) in a Sorvall RC-5C refrigerated centrifuge. The resulting pellets in each bottle were resuspended in 1 ml of DMEM and all 6 ml of suspension (from six tubes) were combined. Viral vector titre determination revealed that the concentrated vector had a titre of 1.3 ± 0.3 × 10 8 TU/ml in comparison to a vector titre of 1 × 10 6 TU/ml from unconcentrated VPC supernatant. The procedure resulted in a 100-fold of vector concentration, demonstrating the feasibility of using PLL treatment for the concentration of large volumes of high-titre vectors.
Gene Therapy 
PLL/lentivector formed complexes that enabled efficient precipitation
To understand how PLL interacted with lentivectors that made precipitation by low-speed centrifugation (10 000 g) possible, we undertook an electron microscopic analysis of the PLL/lentivector precipitates. An immuno-gold staining study with a mouse anti-VSV-G IgG antibody as the primary antibody and a gold-labelled goat antimouse IgG as a secondary antibody revealed that PLL and the lentiviral vector formed complexes, averaging 450-700 m in size. In the complexes, there was an average of three to five viral particles (Figure 3b ), which were bound by PLL. In striking contrast, viral vector particles obtained by ultracentrifugation were free and separate (Figure 3a) . Therefore, we propose that the formation of aggregates of viral vectors with PLL facilitated precipitation at 10 000 g, a condition that does not usually allow viral precipitation.
Transduction of various cells with PLL/lentivector complexes
To investigate further whether viral vectors harvested by PLL treatment were usable for gene transfer we tested the transfer of a marker gene to a variety of cell lines. With a MOI of 10, efficient GFP gene transfer to a variety of cell types including B16, Huh7 and HeLa was 27.5%, 48% and 18.5%, respectively, demonstrating efficient gene transfer. Most importantly, throughout the experiments using the PLL/lentivector complexes, the cells maintained normal cell morphology. There were no signs of any cell toxicity using microscopic analysis.
Further repeated passages of the transduced cells demonstrated that all remained homogenously GFP positive. The GFP level was high during each passage and none of the serial passages showed any decline or change in the intensity of the green fluorescence in the nucleus or the cytoplasm, consistent with stable gene transfer. These data demonstrated the suitability of this method for the preparation of lentivectors for stable gene transfer.
In vivo toxicity study
Analysis of blood chemistry data demonstrated that treatment of animals with vehicle versus vector preparations did not cause significant changes in indicators of hepatic and renal injury. Values for vehicle (n = 4) ver- 
Figure 3 Photographs and schematic representations of PLL/lentivector complexes. Lentivectors obtained by ultracentrifugation or PLL treatment were stained with a mouse anti-VSV-G monoclonal antibody and a gold-labelled rabbit anti-mouse IgG or a gold-labelled protein
Discussion
Lentivectors have been shown to mediate efficient gene deliveries to a variety of cell types in vitro and in vivo. An increasing number of protocols are exploring lentivector gene transfer for gene therapy studies. However, to apply lentivectors for efficient gene transfer and longterm gene expression in large animal studies or human clinical trials in vivo, large volumes of high-titre viral vectors are always needed. In this study, we have developed a new method for harvesting large volumes of high-titre lentivectors by treatment of viral vector supernatant with PLL, followed by low-speed centrifugation. The amounts of PLL added, the duration of incubation, and centrifugation conditions were optimised. Our results demonstrated that PLL at 0.005%, incubation for 30 min, and centrifugation at 10 000 g for 2 h achieved the maximum recovery of high-titre lentivectors. The method is highly efficient and consistent, satisfying the need for large-scale use of lentivectors in clinical laboratories.
PLL and the lentivectors formed complexes in which lentivectors were bound by PLL, which allowed precipitation at 10 000 g for 2 h. At this speed, rotors such as JLA-10 (Avanti J-251 centrifuge; Beckman, CA, USA) or GS-3 (Sorvall RC-5C centrifuge) are ideal for concentration of high-titre vectors from large volumes of supernatant. These rotors take 6 × 500 ml centrifugation bottles, allowing up to 3000 ml to be concentrated in one round of centrifugation over 2 h. Concentration of the same amounts of supernatant by the ultracentrifugation method would have taken 18 rounds (ie AH629 rotor) and more than 50 h of repeated ultra-speed centrifugation. Prolonged handling time of vector supernatants increases the possibility of reduced viability of vectors, damage to vectors, or reduction in the quality of vectors. We are aware that there are other rotors (such as rotor A 841, capacity of 8 × 36 = 288 ml; or rotor A 641, capacity of 6 × 100 = 600 ml) that may have a slightly larger volume capacity than AH629, but generally they have a small volume capacity. Therefore, for the concentration of large volumes of vector such as 3000 ml, or perhaps much larger volumes in a real clinical setting, ultracentrifugation would be impractical to perform.
Retroviruses enter cells through steps beginning with diffusion and binding of the virus particles to a cell surface receptor. These steps are affected by many factors including the specific binding relations between the envelope proteins and cellular receptors, in addition to temperature, pH, medium composition, and the surface charges. Pseudotyping lentivectors with the VSV-G envelope enabled binding of the viral vector to a unique receptor. Previous studies suggest that cationic polymers, such as polybrene, protamine, DEAE-dextran or PLL added to culture medium before or during retroviral vector transduction improved the rate of viral vector binding to its receptor and enhanced transduction efficiency. [24] [25] [26] In this study, our data suggest that the PLL/lentivectors complexes may also facilitate GFP gene transfer via a similar means.
Taken together, our study has shown that, in comparison with ultracentrifugation, the new method has the following advantages. First, it is quick, reducing the time that is needed to handle the vector during the concentration procedure. Second, it has large volume capacity that is especially suitable for the clinical laboratory to prepare large volumes of high-titre viral vector. Third, the formation of PLL/lentivector complexes may have promoted the interactions of the vector with cell surface receptors, enabling efficient gene transfer. We speculate that this approach may also be useful for other viral vectors such as adenovirus vectors and adeno-associated virus, which are widely used in in vivo gene transfer. Therefore, the development of this method is of significance, and likely to be particularly relevant for in vivo gene transfer studies in large animal and in human clinical studies.
Materials and methods
Cell cultures
Cell lines used in this study were a human cervical adeno-carcinoma cell line, HeLa; a human hepatic carcinoma cell line, HUH7; a murine melanoma cell line, B16; and a human embryonic kidney cell line, 293T. All cells were maintained at 37°C in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Invitrogen, CA, USA) containing 2 mm glutamine, 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 g/ml streptomycin with 5% CO 2 . Cells were seeded at 5 × 10 5 on 10-cm plates and were 70-80% confluent at the time of transfection or transduction.
Production of the VSV-G pseudotyped lentiviral vectors
Replication-defective HIV lentiviral vectors were generated by transient cotransfection of 293T cells with the transfer vector plasmid, encoding a marker gene, GFP (pHRЈ CMV-GFP, an HIV-based transfer vector with cytomegalovirus early gene promoter driving the expression of GFP), the packaging construct (pCMV ⌬R 8.2) and the envelope plasmid, encoding VSV-G (pCMV VSV-G, gifts from Drs Tal Kafri and Inder Verma, Salk Institute, SD, USA) using the CaPO4 precipitation method, as reported. 4 The medium was changed 24 h after transfection and VPC supernatant was harvested every 12 h, centrifuged at low speed (1000 g at 5 min) and then filtered through a 0.45-m filter to remove cell debris. The harvested viral vectors were either used directly for transduction as unconcentrated viral vectors or mixed with PLL for concentration experiments or underwent ultracentrifugation for further concentration.
Ultracentrifugation for concentration of lentivectors
This was performed as reported previously. 4 Briefly, 30 ml of VPC supernatant was added to each polypropylene ultracentrifugation tube (6 × 30 ml), and ultracentrifuged at 50 000 g for 2 h at 4°C on AH629 rotors in a Beckman refrigerated centrifuge. After centrifugation, the tubes were promptly removed, supernatant decanted and the pellet was resuspended in 0.6 ml of DMEM.
PLL treatment of viral vector supernatant
PLL hydrobromide (MWvis = 27 400) was purchased from Sigma and a stock solution of 100 mg/ml was made with phosphate-buffered saline (PBS). Various amounts of PLL were added to 10 ml or 30 ml of viral vector suspension with a known viral titre, or 30 ml or 500 ml of VPC supernatant freshly harvested with unknown viral titre, mixed by inversion, and allowed to incubate for different time-periods as described in individual experiments (5 min to 1 h) at 4°C.
In vitro transductions and viral titre determination
To titrate the viral stocks, cultured 293T cells were seeded at 5 × 10 5 cells and transduced with serially diluted, concentrated viral vector stocks 16-18 h after seeding when cells were 70% confluent, unless otherwise noted. For each transduction, 8 g/ml of polybrene (Sigma, St Louis, MO, USA) was included. GFP-positive fluorescent cells were counted using an epifluorescent microscope (Nikon eclipse E600; Japan) with a standard fluorescein isothiocyanate (FITC) excitation-emission filter set at 470 nm. Viral vector titre was determined as the average number of GFP-positive cells per 20 1-mm 2 fields multiplied by a factor to account for plate size, and dilution of the viral stock. Viral vector titre was also determined by a p24 assay as reported previously. 8 An enzymelinked immunosorbent assay (ELISA) was used to determine p24 value of each lentivector stock, following the manufacturer's instructions (NEN, Life Science Products, St Louis, MO, USA). Standard curves were generated using the p24 reagent supplied in the kit. When samples of virus stocks were assayed, p24 values were determined from the linear range of the standard curve.
Electron microscopic analysis of lentivector precipitates
Samples of concentrated, VSV-G pseudotyped lentiviral vectors obtained either by ultracentrifugation or PLL treatment were processed using an immuno-labelling gold staining technique. Ten l of each sample was placed on glow-discharged carbon-coated 400-mesh copper grids for 5 min. The solution was removed with filter paper, and the grid was washed twice with 5% FCS/PBS for 5 min, then incubated with a mouse anti-VSV-G monoclonal antibody (10 g/ml in 5% FCS/PBS, clone P5D4; Boehringer Mannheim, USA) for 1 h. The grids were washed 4 × 1 min with 2% FCS/PBS, and incubated with a gold-labelled, rabbit anti-mouse IgG or a gold-labelled protein A (gifts from Dr J Mackenzie, SASVRC, Royal Children's Hospital, Brisbane) at 1:20 dilution in 5% FCS/PBS for 90 min. Finally, the grids were further washed and examined by Mr C Winterford, Electron Microscopic Unit, Department of Pathology, University of Queensland, Australia.
In vivo toxicity study Balb female mice (8-10 weeks old) were obtained from ARC (West Australia). The liver of mice were exposed through a ventral midline incision; 200 l saline or saline containing 2 × 10 8 viral vector particle was manually injected over~30 s into the portal or inferior vena vein using a 30-gauge, . inch needle. One drop of Vetbond (3M; Animal Care Products, St Paul, MN, USA) was applied to adhere to the wound. The livers were removed 7 days after gene delivery, and at the time of tissue collection, a sample of arterial blood was collected and plasma analysed for evidence of hepatic and renal injury as measures of in vivo toxicity. Specifically, alanine transaminase (ALT) and aspartate transaminase (AST) were used as indicators of hepatic injury and blood urea nitrogen (BUN) as an indicator of renal injury. Means ± standard error of the mean (s.e.m.) were calculated for groups of animals injected with vehicle versus vector preparations. Numbers consisted of at least four animals per group. Significance was assessed as P Ͻ 0.05.
Using our method of virus purification, there is a chance that the 'empty' VSV-G envelope may cause some contamination. Removal of this protein was not attempted in the present study. Several studies have indicated that excess VSV-G in itself may act as a bridge that aids fusion of the virus to the cell surface and as such, may have a beneficial role. 27, 28 Its role in our novel preparation method will form part of future studies.
Statistical analysis
Statistical analyses of data were performed with MannWhitney rank sum test (Sigma Stat 2.0; Jandel Scientific). Comparison of mean viral titre was considered statistically significant when the P value was less than 0.05.
